Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma

Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarker of Asthma

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00980707

Enrollment

Registered

2009-09-21

Start date

2009-08-31

Completion date

2010-11-30

Last updated

2012-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Asthma

Keywords

versican, hyaluronan, sputum

Brief summary

The purpose of this study is to determine the role of versican and hyaluronan measurements in induced sputum as biomarkers of asthma. Enroll 10 subjects with mild persistent asthma who are not receiving treatment with a controller therapy.

Detailed description

We will compare spirometry, eNO and sputum measurements of versican and hyaluronan before and after treatment with fluticasone 220 ug/bid.

Interventions

DRUGInhaled corticosteroid (fluticasone)

inhaled fluticasone 220 ug/bid

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Allergic asthma defined as a positive methacholine challenge

Exclusion criteria

* Non-atopic patients

Design outcomes

Primary

Measure	Time frame
Compare hyaluronan and versican in asthmatics versus atopic non-asthmatics.	1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026